Amcinonide
Pronunciation
(am SIN oh nide)
U.S. Brand Names
Cyclocort®
Generic Available
Yes
Canadian Brand Names
Amcort®; Cyclocort®
Use
Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (high potency corticosteroid)
Pregnancy Risk Factor
C
Contraindications
Hypersensitivity to amcinonide or any component of the formulation; use on the face, groin, or axilla
Warnings/Precautions
Adverse systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants or small children; occlusive dressings should not be used in presence of infection or weeping lesions
Adverse Reactions
Frequency not defined.
Dermatologic: Acne, hypopigmentation, allergic dermatitis, maceration of the skin, skin atrophy, striae, miliaria, telangiectasia
Endocrine & metabolic: HPA suppression, Cushing's syndrome, growth retardation
Local: Burning, itching, irritation, dryness, folliculitis, hypertrichosis
Systemic: Suppression of HPA axis, Cushing's syndrome, hyperglycemia; these reactions occur more frequently with occlusive dressings
Miscellaneous: Secondary infection
Overdosage/Toxicology
Symptoms of overdose include cushingoid appearance (systemic), muscle weakness (systemic), osteoporosis (systemic) all with long-term use only. When consumed in excessive quantities for prolonged periods, systemic hypercorticism and adrenal suppression may occur; in those cases, discontinuation and withdrawal of the corticosteroid should be done judiciously.
Drug Interactions
No data reported
Mechanism of Action
Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction
Pharmacodynamics/Kinetics
Absorption: Adequate through intact skin; increases with skin inflammation or occlusion
Metabolism: Hepatic
Excretion: Urine and feces
Dosage
Topical: Adults: Apply in a thin film 2-3 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.
Patient Education
Before applying, gently wash area to reduce risk of infection; apply a thin film to cleansed area and rub in gently and thoroughly until medication vanishes; avoid exposure to sunlight, severe sunburn may occur
Dental Health: Effects on Dental Treatment
No significant effects or complications reported
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Mental Health: Effects on Mental Status
None reported
Mental Health: Effects on Psychiatric Treatment
None reported
Dosage Forms
Cream: 0.1% (15 g, 30 g, 60 g) [contains benzyl alcohol]
Lotion: 0.1% (60 mL)
Cyclocort®: 0.1% (20 mL, 60 mL) [contains benzyl alcohol]
Ointment: 0.1% (30 g, 60 g) [contains benzyl alcohol]
Cyclocort®: 0.1% (15 g, 30 g, 60 g) [contains benzyl alcohol]
International Brand Names
Amciderm® (DE, TH); Amcort® (CA); Amicla® (BE, LU); Cyclocort® (CA); Cycloderm® (BE); Visderm® (AR); Visisderm® (TH)
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's
accreditation program
is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s
editorial process
. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
|
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
